Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: RXST.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

RxSight (RXST) Stock Forecast and AI Rating

Deep analysis published Sep 20 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

STRONG BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

STRONG BUY

$7.06

+35.8%

2031

5-Year

STRONG BUY

$17

+222.8%

Published batch insight

Cataract Technology Pioneer Trades Below Cash While Razor Blade Consumables Stabilize Enterprise

Research reports show high consensus that valuation is heavily discounted against cash reserves and recurring lens consumable revenues. While collapsing capital equipment placements and clinical chair-time burdens create ongoing headwinds, strategic collaboration milestones and expanding high-margin procedure volumes provide substantial long-term operating support.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Warren Buffett (Value Purist), Universal Investor (Polymath), Michael Burry (Vulture), Superintelligence (Anthropologist), Sherlock Holmes (Whistleblower), J.P. Morgan (Titan), Elon Musk (Visionary), Ray Dalio (Strategist), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in RxSight at publication: $32,281 in five years versus $13,892 for S&P 500 benchmark.

RxSight · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for RxSight compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 5.2 USD1-year price return: +35.83%5-year price return: +222.81%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter / date	Target (USD)	Quarter return	Total return	Forecast rationale
Q118 Dec 2026	5.58	+7.23%	+7.23%	Lapse of the initial partnership refundability window secures liquid cash reserves above two hundred million dollars. Modest tax-loss selling exhausts as quantitative value screens recognize negative enterprise value, initiating early short-covering off depressed valuation lows.
Q218 Mar 2027	6.10	+9.36%	+17.27%	Newly appointed executive leadership introduces formal annual commercial guidance, clarifying salesforce restructuring priorities. Stabilizing recurring consumable lens orders and corporate expense discipline reassure institutional investors, narrowing the steep market discount to tangible book value.
Q318 Jun 2027	6.61	+8.38%	+27.09%	First-quarter results demonstrate sequential stabilization in consumable lens implant volumes across established surgical accounts. Steady gross margins above seventy-five percent mitigate high borrowing cost headwinds, validating that the razor-and-blade model is decoupling from hardware sales.
Q418 Sept 2027	7.06	+6.87%	+35.83%	Targeted clinical support teams improve per-device lens utilization despite summer procedure seasonality. Progress on partner co-development milestones reassures markets regarding pipeline durability, supporting gradual valuation multiple expansion as quarterly operating cash burn steadily contracts.
Q518 Dec 2027	7.60	+7.62%	+46.17%	Fourth-quarter elective surgical volume expands as patients utilize healthcare deductibles. Advancement in preclinical hybrid lens formulations directly addresses surgeon chair-time concerns, while contained administrative overhead reinforces investor confidence in multi-year balance sheet runway.
Q618 Mar 2028	8.27	+8.74%	+58.95%	Full-year reporting confirms annual operating cash burn narrowed significantly as high-margin consumable sales outpaced hardware revenue. Preserved liquidity exceeding one hundred eighty million dollars dispels lingering solvency fears, prompting initial rating upgrades from sell-side analysts.
Q718 Jun 2028	9.05	+9.50%	+74.05%	Achievement of technical feasibility criteria unlocks the first substantial partner development milestone, injecting non-dilutive capital. Tangible partnership execution reinforces the strategic value of proprietary adjustable optics, accelerating institutional accumulation across fundamental healthcare portfolios.
Q818 Sept 2028	9.46	+4.47%	+81.83%	Competitive lens trialing by multinational incumbents temporarily moderates domestic procedure acceleration. However, disciplined operational spending and expanding international shipments to private Australian and European clinics defend consolidated gross margins near seventy-six percent.
Q918 Dec 2028	10.04	+6.18%	+93.07%	Consumable lens procedures cross eighty percent of total corporate product revenue, cementing high-margin annuity characteristics. Year-end surgical demand combined with preliminary regulatory submissions for streamlined adjustment workflows strengthens multi-year earnings visibility.
Q1018 Mar 2029	10.75	+7.09%	+106.76%	Full-year results demonstrate the company approaching operating cash-flow neutrality, eliminating residual fears of dilutive equity financing. Operating leverage takes hold as recurring gross profits absorb baseline commercial infrastructure, supporting enterprise valuation re-rating.
Q1118 Jun 2029	11.46	+6.58%	+120.36%	Commercial roll-out of streamlined adjustment software reduces surgeon chair time across high-volume ambulatory centers. Enhanced practice throughput accelerates consumable lens reorders, while international distribution partnerships begin contributing high-margin incremental revenue.
Q1218 Sept 2029	11.94	+4.20%	+129.62%	Moderating benchmark interest rates alleviate borrowing pressures for ophthalmic practices, spurring selective light delivery console placements. Rebounding hardware sales augment expanding recurring consumable volume, driving double-digit revenue growth and expanding gross profit margins.
Q1318 Dec 2029	12.59	+5.46%	+142.15%	Partner regulatory filings for co-developed presbyopia-correcting lenses advance toward commercial clearance, validating global market potential. Maturing razor-and-blade economics deliver sustained positive free cash flow, transforming the company into a self-funding medtech operator.
Q1418 Mar 2030	13.26	+5.28%	+154.94%	Audited annual statements confirm the company's first full year of positive GAAP operating income. Demonstrating durable owner earnings validates management's turnaround strategy, attracting long-term growth-at-a-reasonable-price healthcare funds and expanding valuation multiples.
Q1518 Jun 2030	13.98	+5.49%	+168.94%	Regulatory approvals for the partner co-developed presbyopia lens trigger substantial milestone revenue. High-margin development income bolsters cash reserves, while commercial preparations begin across the partner's extensive global ophthalmology sales network.
Q1618 Sept 2030	14.43	+3.21%	+177.57%	High-volume cataract clinics increasingly standardize on post-operative adjustability to eliminate residual refractive error. Market share gains in the premium presbyopia segment reinforce pricing power, maintaining corporate gross margins comfortably above seventy-seven percent.
Q1718 Dec 2030	15.06	+4.32%	+189.56%	Initial global commercial shipments of co-developed lenses activate high-margin thirty percent royalty streams. Robust seasonal surgical volumes and royalty inflows accelerate EBITDA margin expansion, prompting board discussions regarding potential share repurchase authorizations.
Q1818 Mar 2031	15.64	+3.85%	+200.71%	Full-year financial reporting highlights double-digit return on invested capital driven by capital-light consumable growth and royalty revenue. Transparent cash generation and expanding royalty predictability command an expanded valuation multiple from broader equity markets.
Q1918 Jun 2031	16.23	+3.80%	+212.13%	International royalty revenue scales across European and Asian markets through the partner's dominant commercial channels. Strong operating cash flows fully fund ongoing optical research while preserving a pristine debt-free balance sheet with abundant liquidity.
Q2018 Sept 2031	16.79	+3.42%	+222.81%	The company concludes the five-year horizon as a profitable, established leader in customized ophthalmic optics. Sustained free cash flow compounding, royalty duration, and strategic acquisition appeal firmly anchor equity valuation at normalized medtech multiples.

The core economic case rests on an asymmetry between distressed hardware multiples and an expanding high-margin consumable procedure annuity. Market pricing conflates capital equipment placement deceleration at ambulatory surgery centers with terminal technology obsolescence, discounting substantial liquid reserves and strategic partnership backing. As commercial salesforce realignment prioritizes account utilization over console pushes, high-margin lens consumables decouple operating performance from clinic capital budgets. The principal counterargument centers on persistent surgeon chair-time friction and incumbent portfolio bundling, which threaten to cap clinical adoption velocity before internal cash flow achieves self-funding operating breakeven.

Key insights

Installed base razor-and-blade economics generate seventy-five percent gross margins, ensuring each incremental procedure delivers powerful operating leverage that steadily compresses headline accounting deficits.
Externalized international distribution and co-development commitments lower internal capital requirements while securing prospective high-margin licensing royalties without dilutive corporate equity financing rounds.
Workflow bottlenecks from multi-visit post-operative adjustments remain the critical operational risk, requiring pipeline biomaterial improvements to permanently unlock high-throughput ophthalmic surgical practices.

Deep Dive

The prevailing market narrative treats the company as a broken growth story whose capital equipment model stalled permanently amid restrictive interest rates and executive turnover. Wall Street consensus anchors heavily on 2025 revenue guidance cuts, withdrawn future outlooks, and ongoing securities litigation, assuming persistent operating losses will exhaust liquid assets before post-operative lens adjustability can surmount clinician workflow friction.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates value through pronounced underpricing, pricing the equity near its net liquid assets while assigning negligible value to the operating business. The decisive analytical blind spot conflates cyclical hardware placement resistance with clinical obsolescence. In reality, over eleven hundred installed devices drive high-margin recurring lens consumables, while strategic alliance funding provides non-dilutive balance sheet support. The strongest counterargument remains that persistent clinician chair-time resistance and rival extended-depth lens bundling could permanently restrict procedure growth to a low-volume niche.

Repricing catalyst

The primary convergence catalyst is the reinstatement of formal annual guidance in early 2027 demonstrating sequential stabilization in consumable lens procedure volume and narrowed quarterly cash burn. Verification that the strategic collaboration survives its initial refundability period, coupled with reportable co-development milestones and commercial salesforce reorientation around practice utilization, will dismantle terminal bankruptcy narratives and force institutional capital to re-rate the operating enterprise above cash value.

Published consensus context

Macro regime alignment

The prevailing macroeconomic regime of restrictive interest rates and sticky inflation presents a mixed backdrop. Elevated borrowing costs and tighter hospital budgets suppress ambulatory surgery center capital equipment financing and elective patient upgrade co-pays. However, an unencumbered balance sheet holding over two hundred million dollars in cash insulates the enterprise from debt refinancing distress while generating non-operating interest income.

Published consensus context

Advisor disagreement

The most consequential analytical debate centers on commercial turnaround mechanics and capital efficiency. One perspective argues that new executive leadership and high-margin recurring lens consumables will organically achieve cash-flow neutrality by 2028, supported by non-dilutive partner milestones. Conversely, skeptical assessments assert that doubling salesforce headcount into an entrenched incumbent market will accelerate quarterly cash burn beyond fifteen million dollars while partner agreements carry contractual refund and termination risks. Resolving this tension requires tracking whether lens implants per installed console stabilize across upcoming quarters without requiring operational expense growth.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Strategic alliance monetization and validation: The strategic partnership injects sixty million dollars in upfront liquidity with up to one hundred forty million in contingent development milestones and thirty percent commercial royalties. This alliance validates proprietary adjustable optic technology, bypasses standalone international sales overhead, and provides non-dilutive capital that accelerates the trajectory toward operating cash-flow breakeven. Expected impact: +65%.
Consumable razor-blade margin expansion: Over eleven hundred installed light delivery consoles anchor a captive stream of recurring lens procedures carrying gross margins above seventy-five percent. As revenue mix shifts decisively toward consumable implants, cash generation decouples from volatile equipment cycles, allowing incremental procedure volume to deliver powerful operating leverage directly to company earnings. Expected impact: +50%.
Commercial realignment under veteran leadership: Executive leadership restructuring pivots commercial strategy from pushing six-figure hardware consoles to optimizing lens utilization across existing clinic accounts. Realigning clinical support teams directly tackles customer onboarding and workflow friction, restoring predictability to domestic procedure volumes and reducing cash burn while rebuilding institutional credibility with financial markets. Expected impact: +40%.
Demographic expansion in cataract surgery: Aging global demographics expand baseline cataract surgical volume, while patient demand for spectacle independence fuels premium intraocular lens conversion. Post-operative adjustability eliminates refractive surprise, granting surgeons superior visual precision over static toric lenses. This clinical differentiation supports premium self-pay pricing power and sustains dependable multi-year procedure demand. Expected impact: +30%.

Top frictions and headwinds

Post-operative clinic chair-time bottleneck: Requiring multiple post-operative UV light adjustment visits and weeks of protective eyewear compliance imposes heavy chair-time friction on busy ophthalmic practices. Surgeons frequently default to conventional premium lenses to maximize daily surgical throughput. Until streamlined single-visit protocols achieve commercial reality, workflow bottlenecks continue constraining practitioner adoption velocity. Expected impact: -35%.
Elevated interest rates freeze equipment: Elevated benchmark interest rates and stringent healthcare borrowing terms cause ambulatory surgery centers to delay six-figure capital equipment acquisitions. Light delivery console placements contracted sharply, extending sales cycles and depressing upfront hardware revenue. This capital rationing slows new practice onboarding and caps near-term expansion into unpenetrated surgical territories. Expected impact: -30%.
Aggressive incumbent portfolio bundling defense: Multinational ophthalmology incumbents fiercely defend premium market share through aggressive pricing rebates and bundling intraocular lenses with phacoemulsification systems. Established competitors leverage extensive sales forces and clinical relationships to promote extended-depth lenses that require zero post-operative adjustments, capping pricing power and increasing standalone customer acquisition costs. Expected impact: -25%.
Discretionary patient copayment affordability strain: Premium intraocular lenses require several thousand dollars in out-of-pocket patient copayments not covered by standard healthcare insurance. Sticky headline inflation and pressurized household disposable income prompt cost-conscious elderly patients to choose standard covered monofocal lenses. This consumer budget sensitivity dampens elective upgrade conversion rates across community ophthalmic clinics. Expected impact: -20%.

Tail risks

Collaboration agreement termination and refund: Technical hurdles or strategic divergence prompt the corporate partner to terminate the co-development agreement during review phases, forfeiting up to one hundred forty million dollars in milestones and demanding partial upfront capital refunds. The loss of strategic validation would shatter market confidence, draining cash reserves and triggering severe multiple compression toward distressed liquidation values. Probability: +25%. Expected impact: -50%.
Biomaterial phototoxicity regulatory safety recall: An unexpected emergence of late-onset retinal phototoxicity or lens material degradation triggers an FDA investigation, black-box safety warning, or product recall. Regulatory intervention would halt elective patient scheduling overnight, induce surgeon boycotts, and unleash substantial product liability claims that overwhelm balance sheet reserves and permanently impair enterprise earning power. Probability: +15%. Expected impact: -65%.

Tail opportunities

Strategic buyout by multinational partner: Following successful early co-development milestones, the multinational partner or another global ophthalmic major launches an outright acquisition of the company to secure proprietary adjustable optics and eliminate future royalty obligations. Given depressed enterprise valuation trading near cash reserves, a takeover offer would deliver an immediate control premium, realigning equity value with historical medical technology transaction multiples. Probability: +30%. Expected impact: +120%.
Single-session UV adjustment clearance: Securing regulatory clearance for next-generation light delivery algorithms and polymer chemistry collapses the multi-session adjustment protocol into a single post-operative treatment without protective glasses. Eliminating clinic chair-time friction removes the primary surgeon barrier, unleashing adoption across high-volume cataract practices and doubling annual consumable procedure volumes within twenty-four months. Probability: +25%. Expected impact: +85%.

What to monitor

Thesis watchpoints

-- Quarterly consumable lens shipments exceeding twenty-eight thousand units across early 2027 confirms utilization stabilization across installed surgical accounts.

Key insights

Quarterly operating cash burn expanding beyond fifteen million dollars through mid-2027 signals ineffective commercial spending controls and deteriorating operating leverage.
Partner termination notices or formal milestone refund demands before mid-2027 require immediate structural reassessment of platform valuation and commercial solvency.

Company Financial Analysis

RxSight Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Headline financial results show a business navigating a major commercial pivot. Trailing revenue contracted to one hundred twenty-eight million dollars as clinic console purchases fell forty-eight percent in fiscal 2025. However, underlying consumable lens procedure volume grew twelve percent, providing a stable foundation beneath hardware volatility. Second-quarter 2026 revenue stabilized at thirty-three million seven hundred thousand dollars, aided by initial partnership licensing payments. This transition conceals improving underlying business quality behind headline accounting losses. Operating losses reached fifty-five million dollars over the trailing twelve months due to commercial expansion and legal costs. However, cash burn runs at roughly half that level because stock compensation is non-cash, and recurring lens sales are gradually replacing hardware as the primary revenue engine.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 134.5M	USD -38.9M	USD -19.3M
2024	USD 139.9M	USD -27.5M	USD -22.4M
2023	USD 89.1M	USD -48.6M	USD -46.4M
2022	USD 49M	USD -66.8M	USD -61.2M
2021	USD 22.6M	USD -48.7M	USD -46.6M

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	--	TTM	Loss-making	USD / USD
2024	--	TTM	Loss-making	USD / USD
2023	--	TTM	Loss-making	USD / USD
2022	--	Annual	Loss-making	USD / USD
2021	--	Annual	Loss-making	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Gross profit margins tell a remarkable story of structural improvement beneath headline operating deficits. Corporate gross margins surged from seventy point seven percent in 2024 to seventy-six point six percent in 2025, reaching seventy-six point seven percent in mid-2026. This expansion reflects an advantageous mix shift toward proprietary consumable lenses, which deliver significantly higher profitability than capital delivery consoles. Operating margins remain temporarily depressed at negative thirty-five point eight percent due to dedicated commercial sales infrastructure. However, product unit economics remain robust. As high-margin recurring lens procedures expand across the installed machine base and licensing income flows through with minimal added costs, operating leverage will steadily convert gross profits into sustainable operating earnings.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD -48.2M	-35.8%	-29.0%
2024	USD -36.9M	-26.3%	-19.6%
2023	USD -50.1M	-56.2%	-54.6%
2022	USD -63.3M	-129.2%	-136.2%
2021	USD -52.8M	-233.6%	-215.5%

Balance sheet and leverage

AI Review

The balance sheet stands as an unencumbered fortress that directly contradicts market distress. The company held two hundred eight million eight hundred thousand dollars in cash and short-term investments as of June 2026, with virtually zero funded bank debt. Total stockholders' equity stood at two hundred seventy-six million dollars, providing an overwhelming liquidity cushion relative to liabilities. Importantly, headline net cash exceeds the company's entire market capitalization, creating a rare net-net valuation floor. While fifty million dollars of partnership capital remains subject to conditional refund terms, trailing free cash burn of twenty-seven million dollars provides several years of operating runway. This liquidity eliminates near-term insolvency risk and shields shareholders from dilutive emergency financing.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 11M	USD 228.1M	USD 8.9M net cash	10.95x
2024	USD 12.3M	USD 237.2M	USD 4.4M net cash	11.36x
2023	USD 3M	USD 127.2M	USD 6.7M net cash	8.06x
2022	USD 45M	USD 105.8M	USD 33.2M net debt	7.81x
2021	USD 44.9M	USD 159.3M	USD 20.6M net debt	15.92x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Physical capital requirements remain exceptionally low, with property and equipment expenditures consuming just under three percent of annual revenue. Manufacturing facilities in California are fully built out, allowing unit lens production to scale without expensive plant construction. Management directs cash into intangible engineering and optical algorithms rather than heavy machinery, keeping physical assets light and capital efficiency high. Crucially, ongoing research and development spending of thirty-eight million five hundred thousand dollars sustains platform enhancements to reduce patient clinic visits. By partnering with a global ophthalmic leader, the company externalizes expensive international distribution and clinical trial expenses onto its partner. This collaborative structure shields internal cash reserves while preserving substantial downstream commercial participation.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 3.8M	USD 38.5M
2024	USD 5.4M	USD 34.4M
2023	USD 4.8M	USD 29.1M
2022	USD 2.4M	USD 26M
2021	USD 1.9M	USD 24.5M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	STRONG_BUY	333	+41.2%	Not available	ORIGINAL
5Y	STRONG_BUY	325	+297%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	4.89	5.65	6.14	14
+6M	March 18, 2027	4.99	6.22	7	14
+9M	June 18, 2027	5.48	6.78	7.83	14
+1Y	September 18, 2027	5.44	7.34	8.62	14
+15M	December 18, 2027	5.77	8.01	9.39	14
+18M	March 18, 2028	6.05	8.72	10.7	14
+21M	June 18, 2028	6.48	9.62	12.42	14
+2Y	September 18, 2028	6.22	10.33	13.78	14
+27M	December 18, 2028	6.53	11.09	15.85	14
+30M	March 18, 2029	6.79	11.9	17.75	14
+33M	June 18, 2029	6.99	12.76	19.35	14
+3Y	September 18, 2029	6.78	13.6	22.06	14
+39M	December 18, 2029	7.12	14.51	24.26	14
+42M	March 18, 2030	7.41	15.36	27.17	14
+45M	June 18, 2030	7.63	16.36	29.35	14
+4Y	September 18, 2030	7.78	17.24	32.58	14
+51M	December 18, 2030	8.09	18.08	34.86	14
+54M	March 18, 2031	8.34	18.89	38.34	14
+57M	June 18, 2031	8.5	19.76	40.64	14
+5Y	September 18, 2031	8.76	20.64	44.3	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The analytical consensus identifies a common pattern: extreme valuation compression relative to liquid cash and resilient gross margins, paired with severe hardware placement deceleration. Heavily weighted analyses emphasize audited SEC filings, verifying that over two hundred million dollars in liquidity provides multi-year runway while recurring lens consumables decouple from capital equipment cycles. The strongest credible contrarian insight stresses that partnership capital is partially encumbered by refund liabilities and that aggressive commercial salesforce expansion could accelerate cash burn before chair-time bottlenecks resolve. Reports were downweighted where they lacked source receipts, assumed unverified near-term revenue tripling, or ignored contractual partnership termination contingencies. Relative allocations therefore prioritize assessments that distinguish recurring lens demand from one-off collaboration accounting while rigorously modeling clinic workflow frictions and equity dilution.

AI RESEARCHER

14.00%Weight

Universal Investor AI

The Polymath

GPT-6 Astra

A top fourteen percent weight is warranted by exemplary evidence quality, verified SEC filings, and balanced causal modeling. The analysis uniquely accounts for refund liabilities encumbering upfront partner receipts, realistic share dilution from executive equity plans, and persistent competitive pressure from alternative implants.

AI RESEARCHER

14.00%Weight

Universal Investor AI

The Polymath

Opus 5

A fourteen percent weight is justified by forensic financial analysis identifying that product gross margins fell to 71.2% excluding collaboration revenue. It provides superior contrarian insight into salesforce overhead expansion risks and scrutinizes contractual non-compete clauses governing partnership milestone payments.

AI RESEARCHER

10.00%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Assigning a ten percent weight reflects rigorous Graham-style net-net valuation and clear causal analysis of consumable margin stabilization. The report accurately evaluates liquid reserves against enterprise value while prudently recognizing that capital equipment sales remain constrained by clinic financing hurdles.

AI RESEARCHER

10.00%Weight

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

A ten percent weight rewards forensic disaggregation of hardware placement declines from resilient consumable lens procedure volumes. The report integrates verified trading and SEC documentation, providing an objective assessment of negative enterprise value and contained operating cash burn.

AI RESEARCHER

9.00%Weight

Michael Burry AI

The Vulture

Gemini 3.8 Flash

A nine percent weight rewards acute contrarian analysis of negative enterprise value and net working capital protection. The report balances deep-value asymmetry against realistic risks of litigation cash drain and incumbent discounting, offering robust economic rationale for capital preservation.

AI RESEARCHER

8.00%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

An eight percent weight rewards granular analysis of clinical workflow bottlenecks and next-generation hybrid biomaterials. While lacking external source links, the report presents coherent causal modeling of chair-time compression and realistic assessments of partnership milestone timelines across the forecast horizon.

AI RESEARCHER

7.00%Weight

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

A seven percent weight recognizes thorough institutional examination of partner commercialization rails and balance sheet health. However, the path assumes an aggressive multiple re-rating toward three times book value that slightly discounts near-term competitive trialing pressure from entrenched multinational cataract incumbents.

AI RESEARCHER

7.00%Weight

Elon Musk AI

The Visionary

Gemini 3.8 Flash

A seven percent weight reflects strong physical and optical domain insights regarding post-operative polymer adjustments. However, the forecast models an aggressive procedural utilization inflection that understates ambulatory surgery center capital hesitation and ongoing securities litigation defense overhead.

AI RESEARCHER

6.00%Weight

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

A six percent weight reflects sound analysis of commercial execution bottlenecks and installed base utilization. The rationale acknowledges executive leadership changes under Mottiwala while maintaining a measured path, though it lacks direct SEC filing verification to support a larger allocation.

AI RESEARCHER

6.00%Weight

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

A six percent weight incorporates rigorous debt-cycle and macroeconomic regime analysis. The report effectively articulates how high interest rates freeze clinic capital budgets while net cash protects corporate solvency, though its scenario path relies on unverified revenue acceleration.

AI THINKER

5.00%Weight

Universal Investor AI

The Polymath

Gemini 3.8 Flash

A five percent weight reflects sound razor-and-blade commercial framing and balance sheet resilience. However, the report lacks external research citations and underweights potential clinical workflow delays in developing next-generation single-session light adjustment protocols.

AI RESEARCHER

4.00%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

A four percent weight captures thoughtful qualitative evaluation of surgeon behavioral friction and chair-time resistance. Nevertheless, the absence of independent research receipts and an optimistic long-term multiple trajectory warrant a modest relative weighting in the synthesis.

AI THINKER

0.00%Weight

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

A zero weight is justified because the report provides no independent research sources or primary regulatory verification. Furthermore, its seven-hundred-percent five-year return trajectory assumes flawless multiple expansion while overlooking material partnership refund liabilities and persistent surgeon chair-time bottlenecks.

AI THINKER

0.00%Weight

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

A zero weight is assigned due to the complete absence of independent source receipts and vague commercial projections. The thesis assumes rapid multiple re-expansion without addressing contractual refund liabilities, ongoing executive restructuring, or recent quarterly product revenue contractions.

Research Provenance

References & Context

This RxSight consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 106 deduplicated sources retained for this batch.

01Premarket Approval (PMA)accessdata.fda.gov
02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
0310-Qsec.gov
048-Ksec.gov
058-Ksec.gov
06EX-10.3sec.gov
07RxSight, Inc. - Form 10-Q - FY2026sec.gov
08RxSight, Inc. - Form 8-K - FY2026sec.gov
09RxSight, Inc. - Form 8-K - FY2026sec.gov
10www.sec.govsec.gov
11RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook - BioSpacebiospace.com
12RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook By Investing.comca.investing.com
13RxSight (NASDAQ:RXST) Cut to Sell at Wall Street Zen - Daily Politicaldailypolitical.com
14RxSight, Inc. (RXST) Stock Analysis: Evaluating The 46% Potential Upside In Medical Device Innovationdirectorstalkinterviews.com
15RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...finance.yahoo.com

And 91 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2019-12-31–2025-12-31, 7 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.